Share

FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management

On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who...
Share

Endocrine Society Works to Advance Obesity Legislation in Congress

The Endocrine Society continues to be a vocal advocate to advance legislation that would address prevention and treatment of obesity. In late July, legislation known as the Treat and Reduce Obesity Act (TROA) that the Society endorsed was introduced in the House and the Senate. This important bipartisan legislation would take steps to ensure that...
Share

Obesity Appears to Increase the Risk of Developing Polycystic Ovary Syndrome

Obesity appears to increase the risk of developing polycystic ovary syndrome (PCOS), according to a study presented at ENDO 2023. An estimated 7% to 10% of all reproductive-aged women globally have PCOS. Women with PCOS have a hormonal imbalance and metabolism problems that may affect their overall health, appearance, and fertility. PCOS is associated with health...
Share

Light or Moderate Alcohol Use Does Not Guard Against Diabetes, Obesity

People who have just one or two drinks per day are not protected against endocrine conditions such as obesity and type 2 diabetes, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Alcohol consumption is a significant public health concern because it is related to many medical conditions such as...
Share

Employees with Obesity May Have Higher Loss of Work Productivity

People with obesity may have lower work productivity due to increased risk of illness, contributing to increased costs for employers, according to industry-supported research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting, in Chicago, Ill. Obesity is a significant public health issue affecting approximately 42% of people in the United States. Employees...